

Expert Perspectives: Sequencing Treatments in Patients With HER2+ Metastatic Breast Cancer



WEDNESDAY, 14 MAY 2025 | 11:30–12:30 CEST | HYBRID

**International Congress Center of the Munich Messe
Munich, Germany | Room 5**

OVERVIEW

Join leading experts Drs Mueller, Criscitiello, and Borges for an interactive 1-hour symposium dedicated to the clinical decision-making process in the third-line setting for patients with HER2+ metastatic breast cancer (MBC). This session will delve into the complexities of treatment sequencing focusing on current treatment guidelines, the latest treatment data, and the value of real-world evidence to inform decision-making, including case-based scenarios for clinical practice implementation. Enhance your knowledge and clinical practice in patients with HER2+ MBC through this engaging and informative expert discussion.

AGENDA

Welcome and Introduction

Volkmar Mueller, MD

Where Are We Today: Understanding the Evolving Treatment Landscape of HER2+ MBC

Carmen Criscitiello, MD, PhD

How Do You Treat? Expert Insights Into Clinical Decision-Making in 3L HER2+ MBC

Virginia Borges, MD

Expert Panel Q&A on Clinical Decision-Making in 3L HER2+ MBC

All faculty

Looking Into the Future of HER2+ MBC

Volkmar Mueller, MD

Panel Discussion and Audience Q&A

All faculty

Closing Remarks

Volkmar Mueller, MD

FACULTY



Volkmar Mueller, MD [CHAIR]

Department of Gynecology and University Breast Center
University Medical Center Hamburg-Eppendorf
Hamburg, Germany



Carmen Criscitiello, MD, PhD

University of Milan
European Institute of Oncology (IEO), IRCCS
Milan, Italy



Virginia Borges, MD

University of Colorado Cancer Center
Aurora, Colorado, USA